<DOC>
	<DOCNO>NCT00033475</DOCNO>
	<brief_summary>RATIONALE : Some type lymphoproliferative disease associate Epstein-Barr virus . Combining reduced immunosuppressive therapy donor white blood cell treat laboratory kill cell infect Epstein-Barr virus may effective treatment lymphoproliferative disease . PURPOSE : Randomized phase III trial compare effectiveness reduce immunosuppressive therapy without donor white blood cell treat patient Epstein-Barr virus-associated lymphoproliferative disease organ transplantation .</brief_summary>
	<brief_title>Reduced Immunosuppressive Therapy With Without Donor White Blood Cells Treating Patients With Lymphoproliferative Disease After Organ Transplantation</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy treatment partially HLA-matched allogeneic cytotoxic T cell reduction immunosuppression , term survival rate time remission patient Epstein-Barr virus-associated B-cell lymphoproliferative disease solid organ transplantation . OUTLINE : This randomize , multicenter study . Patients stratify accord transplant organ type transplant center . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo sliding-scale reduction immunosuppressive drug 1 5 regimen physician 's discretion . Patients receive partially HLA-matched allogeneic cytotoxic T cell IV 5 minute weekly total 4 week . - Arm II : Patients undergo reduction immunosuppression arm I alone . Patients follow monthly 6 month every 3 month 2 year . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis posttransplant lymphoproliferative disease ( PTLD ) solid organ ( heart , heart/lung , liver , liver/gut , pancreas , kidney ) transplantation EpsteinBarr viruspositive tumor Newly diagnose disease Measurable disease clinical method radiography Must partially match donor cytotoxic T cell ( CTL ) available No known panel reactivity HLA type CTL available therapy PATIENT CHARACTERISTICS : Age : Any age Performance status : Karnofsky 20100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No prior therapy PTLD No concurrent antiviral drug ( e.g. , acyclovir ganciclovir ) PTLD</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>post-transplant lymphoproliferative disorder</keyword>
</DOC>